Table 1.
Targets for cholangiocarcinoma cells.
| Preclinical Study | Clinical Study | |||||
|---|---|---|---|---|---|---|
| Name | Type | ADC | ADC-Payload | PIT | ADC | ADC-Payload |
| HER2 | Receptor | ✓ | Emtansine (DM1) | ✓ | ✓ | Emtansine (DM1) Deruxtecan (DXd) |
| EGFR | Receptor | ✓ | ||||
| FGFR2 | Receptor | ✓ | Ixadotin | |||
| MUC1 | Secretion (mucin) | ✓ | ||||
| Glypican-1 (GPC1) | Secretion (proteoglycan) | ✓ | Monomethyl auristatin F (MMAF) |
|||
| CD133/ prominin-1 |
Secretion (glycoprotein) | ✓ | Maleimidocaproyl-valine-citrulline-p-aminobenzoyl-MMAF (vcMMAF) | |||
| TROP2 | Secretion (glycoprotein) | ✓ | ||||
HER2—human epidermal growth factor receptor 2; EGFR—epidermal growth factor receptor; FGFR2—fibroblast growth factor receptor-2; MUC1—transmembrane glycoprotein mucin 1; TROP2—trophoblast cell surface antigen 2. ✓ indicates the existence of previous reports.